UNSPSC 51101659: Fexinidazole

This classification denotes an antiprotozoal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 306ERL82IR. European Medicines Agency schedules Fexinidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07618MIG. Fexinidazole generally arises in the molecular formula C12H13N3O3S.

UNSPSC 51101659 Fexinidazole (Commodity) covers pharmaceutical products procured by state and local health agencies, though recent state and local solicitations tagged to this code show limited activity directly aligned with fexinidazole itself. The recent opportunities posted under this code involve naloxone and safe drug deactivation systems procured by a county public health authority, and a completed pharmaceutical warehouse piggyback contract through a multi-state cooperative purchasing consortium. State and local health departments and county public health offices are the primary issuing bodies active in this space, with cooperative purchasing vehicles like MMCAP Infuse providing access to pre-negotiated pharmaceutical supply arrangements for smaller jurisdictions.

Activity under this code appears concentrated in Florida and Illinois, based on recent postings. Seminole County, Florida issued an IFB on June 30, 2026 (response deadline July 26, 2026) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for delivery to the Seminole County Community Health Building in Sanford, with a two-year initial term and one-year renewal option. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract to Chartwell Rx LLC in August 2026 valued at $2,999,999.11 over the full contract term (12 months initial plus two renewal years) for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets through the MMCAP Infuse consortium. Neither procurement applied explicit set-aside designations or domestic product preferences.